Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MSCI Inc.MSCI · Entity 3075 | Director · Chairman and CEO | May 15, 2026 | May 18, 2026 |
| Royalty Pharma plcRPRX · Entity 3100 | Director | June 30, 2025 | June 30, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MSCI Inc.
Report date May 15, 2026 · Filed May 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,731,961 |
Ending reported balance
After 2026-05-15 transaction · row 7
7 source rows · reconciled sequenceRow 1 · 2026-05-15 · Purchase · Acquired 120 · Balance 1,728,081 F1: This transaction was executed in multiple trades at prices ranging from $558.85 to $559.83. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request, to the SEC staff, the issuer or the security holders of the issuer full information regarding the number of shares and prices at which each transaction was effected. Row 2 · 2026-05-15 · Purchase · Acquired 240 · Balance 1,728,321 F2: This transaction was executed in multiple trades at prices ranging from $559.90 to $560.75. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request, to the SEC staff, the issuer or the security holders of the issuer full information regarding the number of shares and prices at which each transaction was effected. Row 3 · 2026-05-15 · Purchase · Acquired 1,238 · Balance 1,729,559 F3: This transaction was executed in multiple trades at prices ranging from $560.91 to $561.88. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request, to the SEC staff, the issuer or the security holders of the issuer full information regarding the number of shares and prices at which each transaction was effected. Row 4 · 2026-05-15 · Purchase · Acquired 1,122 · Balance 1,730,681 F4: This transaction was executed in multiple trades at prices ranging from $562.01 to $562.96. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request, to the SEC staff, the issuer or the security holders of the issuer full information regarding the number of shares and prices at which each transaction was effected. Row 5 · 2026-05-15 · Purchase · Acquired 800 · Balance 1,731,481 F5: This transaction was executed in multiple trades at prices ranging from $563.03 to $563.90. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request, to the SEC staff, the issuer or the security holders of the issuer full information regarding the number of shares and prices at which each transaction was effected. Row 6 · 2026-05-15 · Purchase · Acquired 400 · Balance 1,731,881 F6: This transaction was executed in multiple trades at prices ranging from $564.12 to $564.74. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request, to the SEC staff, the issuer or the security holders of the issuer full information regarding the number of shares and prices at which each transaction was effected. Row 7 · 2026-05-15 · Purchase · Acquired 80 · Balance 1,731,961 F7: This transaction was executed in multiple trades at prices ranging from $565.16 to $565.17. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request, to the SEC staff, the issuer or the security holders of the issuer full information regarding the number of shares and prices at which each transaction was effected. |
| Common StockSEC Table I · non-derivative | IndirectBy Fernandez 2007 Children's Trust | 410,776 |
Reported balance
Holding disclosure · report date 2026-05-15 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 410,776 |
| Common StockSEC Table I · non-derivative | IndirectBy Son | 15,400 |
Reported balance
Holding disclosure · report date 2026-05-15 · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · Balance 15,400 |
| Common StockSEC Table I · non-derivative | IndirectBy Son | 15,400 |
Reported balance
Holding disclosure · report date 2026-05-15 · row 10
Holding and transaction disclosures are not merged.
1 source rowRow 10 · Balance 15,400 |
| Common StockSEC Table I · non-derivative | IndirectBy Daughter | 15,400 |
Reported balance
Holding disclosure · report date 2026-05-15 · row 11
Holding and transaction disclosures are not merged.
1 source rowRow 11 · Balance 15,400 |
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $549.83 · Expires 2032-02-03 | Direct | 29,564 |
Reported balance
Holding disclosure · report date 2026-05-15 · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · Balance 29,564 |
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $554.52 · Expires 2033-02-02 | Direct | 42,193 |
Reported balance
Holding disclosure · report date 2026-05-15 · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · Balance 42,193 |
| Premium option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $1,000.00 · Expires 2035-01-31 | Direct | 36,846 |
Reported balance
Holding disclosure · report date 2026-05-15 · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · Balance 36,846 |
| Premium option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $1,100.00 · Expires 2035-01-31 | Direct | 40,780 |
Reported balance
Holding disclosure · report date 2026-05-15 · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · Balance 40,780 |
| Premium option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $1,200.00 · Expires 2035-01-31 | Direct | 44,920 |
Reported balance
Holding disclosure · report date 2026-05-15 · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · Balance 44,920 |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed in multiple trades at prices ranging from $558.85 to $559.83. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request, to the SEC staff, the issuer or the security holders of the issuer full information regarding the number of shares and prices at which each transaction was effected.
F2: This transaction was executed in multiple trades at prices ranging from $559.90 to $560.75. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request, to the SEC staff, the issuer or the security holders of the issuer full information regarding the number of shares and prices at which each transaction was effected.
F3: This transaction was executed in multiple trades at prices ranging from $560.91 to $561.88. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request, to the SEC staff, the issuer or the security holders of the issuer full information regarding the number of shares and prices at which each transaction was effected.
F4: This transaction was executed in multiple trades at prices ranging from $562.01 to $562.96. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request, to the SEC staff, the issuer or the security holders of the issuer full information regarding the number of shares and prices at which each transaction was effected.
F5: This transaction was executed in multiple trades at prices ranging from $563.03 to $563.90. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request, to the SEC staff, the issuer or the security holders of the issuer full information regarding the number of shares and prices at which each transaction was effected.
F6: This transaction was executed in multiple trades at prices ranging from $564.12 to $564.74. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request, to the SEC staff, the issuer or the security holders of the issuer full information regarding the number of shares and prices at which each transaction was effected.
F7: This transaction was executed in multiple trades at prices ranging from $565.16 to $565.17. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request, to the SEC staff, the issuer or the security holders of the issuer full information regarding the number of shares and prices at which each transaction was effected.
Royalty Pharma plc
Report date June 30, 2025 · Filed June 30, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Ordinary SharesSEC Table I · non-derivative | Direct | 65,324 |
Reported balance
After 2025-06-30 transaction · row 1
1 source rowRow 1 · 2025-06-30 · Grant · Acquired 1,064 · Balance 65,324 F1: Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500. |
| Class A Ordinary SharesSEC Table I · non-derivative | IndirectBy Fernandez 2007 Children's Trust | 58,200 |
Reported balance
Holding disclosure · report date 2025-06-30 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 58,200 |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 31, 2024 Filed Jan 2, 2025 21:28 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 1,503 | $24.94 | $37,487.22 |
DisclosureSEC source: 0001802768-25-000005 · wk-form4_1735853312.xml · nonDerivative · entry 1 Fernandez Henry A · CIK 0001416750 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,505 F1 · price: Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500. Read SEC document |
| December 05, 2024 Filed Dec 9, 2024 06:55 UTC | MSCI Inc. MSCI · Entity 3075 | PurchaseCommon Stock | 493 | $614.08 | $302,741.44 |
DisclosureSEC source: 0001408198-24-000184 · wk-form4_1733745345.xml · nonDerivative · entry 3 Fernandez Henry A · CIK 0001416750 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Fernandez 2007 Children's Trust Disclosed balance after: 330,379 F3 · price: This transaction was executed in multiple trades at prices ranging from $613.93 to $614.16. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request, to the SEC staff, the issuer or the security holders of the issuer full information regarding the number of shares and prices at which each transaction was effected. Read SEC document |
| December 05, 2024 Filed Dec 9, 2024 06:55 UTC | MSCI Inc. MSCI · Entity 3075 | PurchaseCommon Stock | 1,807 | $613.38 | $1,108,377.66 |
DisclosureSEC source: 0001408198-24-000184 · wk-form4_1733745345.xml · nonDerivative · entry 2 Fernandez Henry A · CIK 0001416750 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Fernandez 2007 Children's Trust Disclosed balance after: 329,886 F2 · price: This transaction was executed in multiple trades at prices ranging from $612.93 to $613.92. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request, to the SEC staff, the issuer or the security holders of the issuer full information regarding the number of shares and prices at which each transaction was effected. Read SEC document |
| December 05, 2024 Filed Dec 9, 2024 06:55 UTC | MSCI Inc. MSCI · Entity 3075 | PurchaseCommon Stock | 600 | $610.00 | $366,000.00 |
DisclosureSEC source: 0001408198-24-000184 · wk-form4_1733745345.xml · nonDerivative · entry 1 Fernandez Henry A · CIK 0001416750 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Fernandez 2007 Children's Trust Disclosed balance after: 328,079 F1 · price: This transaction was executed in multiple trades at prices ranging from $609.99 to $610.00. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request, to the SEC staff, the issuer or the security holders of the issuer full information regarding the number of shares and prices at which each transaction was effected. Read SEC document |
| September 30, 2024 Filed Sep 30, 2024 21:07 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 1,342 | $27.92 | $37,475.22 |
DisclosureSEC source: 0001802768-24-000054 · wk-form4_1727730460.xml · nonDerivative · entry 1 Fernandez Henry A · CIK 0001416750 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,002 F1 · balance_after: 1. Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500. Read SEC document |
| June 28, 2024 Filed Jun 28, 2024 21:12 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 1,399 | $26.80 | $37,492.92 |
DisclosureSEC source: 0001802768-24-000042 · wk-form4_1719609121.xml · nonDerivative · entry 1 Fernandez Henry A · CIK 0001416750 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,660 F1 · price: Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500. Read SEC document |
| June 07, 2024 Filed Jun 10, 2024 20:13 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 9,293 | $0.00 | $0.00 |
DisclosureSEC source: 0001802768-24-000031 · wk-form4_1718050428.xml · nonDerivative · entry 1 Fernandez Henry A · CIK 0001416750 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,261 F1 · shares: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder. Read SEC document |
| April 25, 2024 Filed Apr 26, 2024 09:19 UTC | MSCI Inc. MSCI · Entity 3075 | GiftCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001408198-24-000081 · wk-form4_1714137587.xml · nonDerivative · entry 15 Fernandez Henry A · CIK 0001416750 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Son Disclosed balance after: 15,400 F13 · shares: Bona fide gift by the Reporting Person to his younger son. Read SEC document |
| April 25, 2024 Filed Apr 26, 2024 09:19 UTC | MSCI Inc. MSCI · Entity 3075 | GiftCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001408198-24-000081 · wk-form4_1714137587.xml · nonDerivative · entry 14 Fernandez Henry A · CIK 0001416750 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,745,267 F13 · shares: Bona fide gift by the Reporting Person to his younger son. Read SEC document |
| April 25, 2024 Filed Apr 26, 2024 09:19 UTC | MSCI Inc. MSCI · Entity 3075 | GiftCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001408198-24-000081 · wk-form4_1714137587.xml · nonDerivative · entry 13 Fernandez Henry A · CIK 0001416750 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Son Disclosed balance after: 15,400 F12 · shares: Bona fide gift by the Reporting Person to his older son. Read SEC document |
| April 25, 2024 Filed Apr 26, 2024 09:19 UTC | MSCI Inc. MSCI · Entity 3075 | GiftCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001408198-24-000081 · wk-form4_1714137587.xml · nonDerivative · entry 12 Fernandez Henry A · CIK 0001416750 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,752,767 F12 · shares: Bona fide gift by the Reporting Person to his older son. Read SEC document |
| April 25, 2024 Filed Apr 26, 2024 09:19 UTC | MSCI Inc. MSCI · Entity 3075 | GiftCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001408198-24-000081 · wk-form4_1714137587.xml · nonDerivative · entry 11 Fernandez Henry A · CIK 0001416750 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Daughter Disclosed balance after: 15,400 F10 · shares: Bona fide gift by the Reporting Person to his daughter. Read SEC document |
| April 25, 2024 Filed Apr 26, 2024 09:19 UTC | MSCI Inc. MSCI · Entity 3075 | GiftCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001408198-24-000081 · wk-form4_1714137587.xml · nonDerivative · entry 10 Fernandez Henry A · CIK 0001416750 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,760,267 F10 · shares: Bona fide gift by the Reporting Person to his daughter. F11 · balance_after: The balance shown reflects the transfer of 251,543 shares previously indirectly held by The Henry Fernandez 2022 MSCI Annuity Trust, a grantor retained annuity trust established by the Reporting Person, following the termination of The Henry Fernandez 2022 MSCI Annuity Trust, to direct holdings by the Reporting Person. Read SEC document |
| April 25, 2024 Filed Apr 26, 2024 09:19 UTC | MSCI Inc. MSCI · Entity 3075 | PurchaseCommon Stock | 1,644 | $469.66 | $772,121.04 |
DisclosureSEC source: 0001408198-24-000081 · wk-form4_1714137587.xml · nonDerivative · entry 9 Fernandez Henry A · CIK 0001416750 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Fernandez 2007 Children's Trust Disclosed balance after: 327,479 F9 · price: This transaction was executed in multiple trades at prices ranging from $469.06 to $470.00. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request, to the SEC staff, the issuer or the security holders of the issuer full information regarding the number of shares and prices at which each transaction was effected. Read SEC document |
| April 25, 2024 Filed Apr 26, 2024 09:19 UTC | MSCI Inc. MSCI · Entity 3075 | PurchaseCommon Stock | 4,294 | $468.52 | $2,011,824.88 |
DisclosureSEC source: 0001408198-24-000081 · wk-form4_1714137587.xml · nonDerivative · entry 8 Fernandez Henry A · CIK 0001416750 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Fernandez 2007 Children's Trust Disclosed balance after: 325,835 F8 · price: This transaction was executed in multiple trades at prices ranging from $468.04 to $469.03. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request, to the SEC staff, the issuer or the security holders of the issuer full information regarding the number of shares and prices at which each transaction was effected. Read SEC document |
| April 25, 2024 Filed Apr 26, 2024 09:19 UTC | MSCI Inc. MSCI · Entity 3075 | PurchaseCommon Stock | 988 | $467.24 | $461,633.12 |
DisclosureSEC source: 0001408198-24-000081 · wk-form4_1714137587.xml · nonDerivative · entry 7 Fernandez Henry A · CIK 0001416750 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Fernandez 2007 Children's Trust Disclosed balance after: 321,541 F7 · price: This transaction was executed in multiple trades at prices ranging from $467.04 to $468.03. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request, to the SEC staff, the issuer or the security holders of the issuer full information regarding the number of shares and prices at which each transaction was effected. Read SEC document |
| April 25, 2024 Filed Apr 26, 2024 09:19 UTC | MSCI Inc. MSCI · Entity 3075 | PurchaseCommon Stock | 760 | $465.74 | $353,962.40 |
DisclosureSEC source: 0001408198-24-000081 · wk-form4_1714137587.xml · nonDerivative · entry 6 Fernandez Henry A · CIK 0001416750 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Fernandez 2007 Children's Trust Disclosed balance after: 320,553 F6 · price: This transaction was executed in multiple trades at prices ranging from $465.35 to $466.06. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request, to the SEC staff, the issuer or the security holders of the issuer full information regarding the number of shares and prices at which each transaction was effected. Read SEC document |
| April 25, 2024 Filed Apr 26, 2024 09:19 UTC | MSCI Inc. MSCI · Entity 3075 | PurchaseCommon Stock | 1,600 | $464.55 | $743,280.00 |
DisclosureSEC source: 0001408198-24-000081 · wk-form4_1714137587.xml · nonDerivative · entry 5 Fernandez Henry A · CIK 0001416750 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Fernandez 2007 Children's Trust Disclosed balance after: 319,793 F5 · price: This transaction was executed in multiple trades at prices ranging from $463.92 to $464.86. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request, to the SEC staff, the issuer or the security holders of the issuer full information regarding the number of shares and prices at which each transaction was effected. Read SEC document |
| April 25, 2024 Filed Apr 26, 2024 09:19 UTC | MSCI Inc. MSCI · Entity 3075 | PurchaseCommon Stock | 863 | $462.96 | $399,534.48 |
DisclosureSEC source: 0001408198-24-000081 · wk-form4_1714137587.xml · nonDerivative · entry 4 Fernandez Henry A · CIK 0001416750 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Fernandez 2007 Children's Trust Disclosed balance after: 318,193 F4 · price: This transaction was executed in multiple trades at prices ranging from $462.80 to $463.56. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request, to the SEC staff, the issuer or the security holders of the issuer full information regarding the number of shares and prices at which each transaction was effected. Read SEC document |
| April 25, 2024 Filed Apr 26, 2024 09:19 UTC | MSCI Inc. MSCI · Entity 3075 | PurchaseCommon Stock | 1,445 | $461.92 | $667,474.40 |
DisclosureSEC source: 0001408198-24-000081 · wk-form4_1714137587.xml · nonDerivative · entry 3 Fernandez Henry A · CIK 0001416750 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Fernandez 2007 Children's Trust Disclosed balance after: 317,330 F3 · price: This transaction was executed in multiple trades at prices ranging from $461.39 to $462.32. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request, to the SEC staff, the issuer or the security holders of the issuer full information regarding the number of shares and prices at which each transaction was effected. Read SEC document |
| April 25, 2024 Filed Apr 26, 2024 09:19 UTC | MSCI Inc. MSCI · Entity 3075 | PurchaseCommon Stock | 906 | $460.69 | $417,385.14 |
DisclosureSEC source: 0001408198-24-000081 · wk-form4_1714137587.xml · nonDerivative · entry 2 Fernandez Henry A · CIK 0001416750 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Fernandez 2007 Children's Trust Disclosed balance after: 315,885 F2 · price: This transaction was executed in multiple trades at prices ranging from $460.25 to $461.07. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request, to the SEC staff, the issuer or the security holders of the issuer full information regarding the number of shares and prices at which each transaction was effected. Read SEC document |
| April 25, 2024 Filed Apr 26, 2024 09:19 UTC | MSCI Inc. MSCI · Entity 3075 | PurchaseCommon Stock | 500 | $459.48 | $229,740.00 |
DisclosureSEC source: 0001408198-24-000081 · wk-form4_1714137587.xml · nonDerivative · entry 1 Fernandez Henry A · CIK 0001416750 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Fernandez 2007 Children's Trust Disclosed balance after: 314,979 F1 · price: This transaction was executed in multiple trades at prices ranging from $459.24 to $459.64. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request, to the SEC staff, the issuer or the security holders of the issuer full information regarding the number of shares and prices at which each transaction was effected. Read SEC document |
| March 28, 2024 Filed Apr 2, 2024 21:30 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 1,240 | $30.23 | $37,483.09 |
DisclosureSEC source: 0001802768-24-000018 · wk-form4_1712093434.xml · nonDerivative · entry 1 Fernandez Henry A · CIK 0001416750 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,968 F1 · price: Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500. Read SEC document |
| February 05, 2024 Filed Feb 7, 2024 20:09 UTC | MSCI Inc. MSCI · Entity 3075 | Tax withholdingCommon Stock | 4,036 | $583.39 | $2,354,562.04 |
DisclosureSEC source: 0001408198-24-000027 · wk-form4_1707354557.xml · nonDerivative · entry 4 Fernandez Henry A · CIK 0001416750 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,516,224 F5 · shares: Represents shares reacquired by MSCI Inc. to satisfy tax withholding obligations in connection with the vesting and conversion to shares of 7,298 PSUs granted on February 4, 2021 (includes the performance adjustment as described above). Read SEC document |
| February 05, 2024 Filed Feb 7, 2024 20:09 UTC | MSCI Inc. MSCI · Entity 3075 | GrantCommon Stock | 7,298 | $0.00 | $0.00 |
DisclosureSEC source: 0001408198-24-000027 · wk-form4_1707354557.xml · nonDerivative · entry 3 Fernandez Henry A · CIK 0001416750 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,520,260 F4 · shares: Represents the number of shares of common stock issued following the vesting and conversion of PSUs granted to the reporting person on February 4, 2021, upon certification by the Compensation Committee on February 5, 2024 of the achievement of the performance metric for the performance period from February 3, 2021 to February 2, 2024. Read SEC document |
| February 05, 2024 Filed Feb 7, 2024 20:09 UTC | MSCI Inc. MSCI · Entity 3075 | Tax withholdingCommon Stock | 46,465 | $583.39 | $27,107,216.35 |
DisclosureSEC source: 0001408198-24-000027 · wk-form4_1707354557.xml · nonDerivative · entry 2 Fernandez Henry A · CIK 0001416750 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,512,962 F3 · shares: Represents shares reacquired by MSCI Inc. to satisfy tax withholding obligations in connection with the vesting and conversion to shares of 84,022 PSUs granted on February 7, 2019 (includes the performance adjustment as described above). Read SEC document |
| February 05, 2024 Filed Feb 7, 2024 20:09 UTC | MSCI Inc. MSCI · Entity 3075 | GrantCommon Stock | 84,022 | $0.00 | $0.00 |
DisclosureSEC source: 0001408198-24-000027 · wk-form4_1707354557.xml · nonDerivative · entry 1 Fernandez Henry A · CIK 0001416750 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,559,427 F1 · shares: Represents the number of shares of common stock issued following the vesting and conversion of performance stock units ("PSUs") granted to the reporting person on February 7, 2019, upon certification by the Compensation, Talent and Culture Committee (the "Compensation Committee") on February 5, 2024 of the achievement of the performance metric for the performance period from February 6, 2019 to February 5, 2024. F2 · balance_after: The balance shown reflects the transfer of 251,566 shares previously indirectly held by The Henry Fernandez 2022 MSCI Annuity Trust, a grantor retained annuity trust ("GRAT") established by the Reporting Person, to direct holdings by the Reporting Person following a scheduled annuity payment from the GRAT. Read SEC document |
| December 29, 2023 Filed Dec 29, 2023 22:14 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 1,353 | $27.71 | $37,492.98 |
DisclosureSEC source: 0001802768-23-000036 · wk-form4_1703888031.xml · nonDerivative · entry 1 Fernandez Henry A · CIK 0001416750 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,728 F1 · price: Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500. Read SEC document |
| September 29, 2023 Filed Oct 3, 2023 20:25 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 1,384 | $27.08 | $37,475.26 |
DisclosureSEC source: 0001209191-23-051475 · doc4.xml · nonDerivative · entry 1 Fernandez Henry A · CIK 0001416750 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,375 F1 · price: Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500. Read SEC document |
| June 30, 2023 Filed Jun 30, 2023 13:15 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 1,208 | $31.03 | $37,480.98 |
DisclosureSEC source: 0001209191-23-040238 · doc4.xml · nonDerivative · entry 1 Fernandez Henry A · CIK 0001416750 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,991 F1 · price: Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500. Read SEC document |
| June 23, 2023 Filed Jun 26, 2023 20:07 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 7,747 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-039682 · doc4.xml · nonDerivative · entry 1 Fernandez Henry A · CIK 0001416750 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,783 F1 · shares: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder. Read SEC document |
| March 31, 2023 Filed Mar 31, 2023 20:40 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 1,049 | $35.73 | $37,478.25 |
DisclosureSEC source: 0001209191-23-021883 · doc4.xml · nonDerivative · entry 1 Fernandez Henry A · CIK 0001416750 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,036 F1 · price: Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 16:33 UTC | MSCI Inc. MSCI · Entity 3075 | Tax withholdingCommon Stock | 15,746 | $556.90 | $8,768,947.40 |
DisclosureSEC source: 0001209191-23-008419 · doc4.xml · nonDerivative · entry 2 Fernandez Henry A · CIK 0001416750 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,223,839 F2 · shares: Represents shares reacquired by MSCI Inc. to satisfy tax withholding obligations in connection with the vesting and conversion to shares of 28,472 PSUs granted on February 6, 2020 (includes the performance adjustment as described above). Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 16:33 UTC | MSCI Inc. MSCI · Entity 3075 | GrantCommon Stock | 28,472 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-008419 · doc4.xml · nonDerivative · entry 1 Fernandez Henry A · CIK 0001416750 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,239,585 F1 · shares: Represents the number of shares of common stock issued following the vesting and conversion of performance stock units ("PSUs") granted to the reporting person on February 6, 2020, upon certification by the Compensation, Talent & Culture Committee on February 8, 2023 of the achievement of the performance metric for the performance period from February 5, 2020 to February 4, 2023. Read SEC document |
| December 30, 2022 Filed Jan 3, 2023 22:11 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 943 | $39.76 | $37,494.91 |
DisclosureSEC source: 0001209191-23-000324 · doc4.xml · nonDerivative · entry 1 Fernandez Henry A · CIK 0001416750 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,987 F1 · price: Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500. Read SEC document |
| September 30, 2022 Filed Sep 30, 2022 20:25 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 913 | $41.06 | $37,490.43 |
DisclosureSEC source: 0001209191-22-051640 · doc4.xml · nonDerivative · entry 1 Fernandez Henry A · CIK 0001416750 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,044 F1 · price: Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500. Read SEC document |
| June 30, 2022 Filed Jun 30, 2022 10:51 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 903 | $41.52 | $37,492.83 |
DisclosureSEC source: 0001209191-22-039876 · doc4.xml · nonDerivative · entry 1 Fernandez Henry A · CIK 0001416750 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,131 F1 · price: Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500. Read SEC document |
| June 24, 2022 Filed Jun 24, 2022 20:49 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 6,328 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-024032 · doc4.xml · nonDerivative · entry 1 Fernandez Henry A · CIK 0001416750 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,228 F1 · shares: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder. Read SEC document |
| March 31, 2022 Filed Apr 1, 2022 22:29 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 964 | $38.87 | $37,470.97 |
DisclosureSEC source: 0001209191-22-022058 · doc4.xml · nonDerivative · entry 1 Fernandez Henry A · CIK 0001416750 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,900 F1 · price: Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500. Read SEC document |
| February 24, 2022 Filed Feb 26, 2022 00:21 UTC | Royalty Pharma plc RPRX · Entity 3100 | PurchaseClass A Ordinary Shares | 32,500 | $37.49 | $1,218,373.00 |
DisclosureSEC source: 0001209191-22-013383 · doc4.xml · nonDerivative · entry 1 Fernandez Henry A · CIK 0001416750 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Fernandez 2007 Children's Trust Disclosed balance after: 58,200 F1 · price: The price reported in Column 4 is a weighted average price. The reported securities were purchased in multiple transactions at prices ranging from $37.16 to $37.75. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within such range. Read SEC document |
| February 07, 2022 Filed Feb 9, 2022 16:15 UTC | MSCI Inc. MSCI · Entity 3075 | Tax withholdingCommon Stock | 42,460 | $550.45 | $23,372,107.00 |
DisclosureSEC source: 0001209191-22-008021 · doc4.xml · nonDerivative · entry 6 Fernandez Henry A · CIK 0001416750 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,211,113 F5 · shares: Represents shares reacquired by MSCI Inc. to satisfy tax withholding obligations in connection with the vesting and conversion to shares of 80,187 PSUs granted on February 7, 2019 (includes the performance adjustment as described above). Read SEC document |
| February 07, 2022 Filed Feb 9, 2022 16:15 UTC | MSCI Inc. MSCI · Entity 3075 | GrantCommon Stock | 80,187 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-008021 · doc4.xml · nonDerivative · entry 5 Fernandez Henry A · CIK 0001416750 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,253,573 F3 · shares: Represents the number of shares of common stock issued following the vesting and conversion of performance stock units ("PSUs") granted to the reporting person on February 7, 2019, upon certification by the Compensation, Talent & Culture Committee on February 7, 2022 of the achievement of the performance metric for the performance period from February 6, 2019 to February 5, 2022. F4 · balance_after: Reflects the exempt contribution pursuant to Rule 16a-13 by the Reporting Person of 503,109 shares previously directly held to The Henry Fernandez 2022 MSCI Annuity Trust, a grantor retained annuity trust (GRAT) established by the Reporting Person. Read SEC document |
| December 31, 2021 Filed Jan 3, 2022 22:35 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 958 | $39.11 | $37,462.69 |
DisclosureSEC source: 0001209191-22-000300 · doc4.xml · nonDerivative · entry 1 Fernandez Henry A · CIK 0001416750 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,936 F1 · price: Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500. Read SEC document |
| December 21, 2021 Filed Feb 9, 2022 16:15 UTC | MSCI Inc. MSCI · Entity 3075 | GiftCommon Stock | 7,170 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-008021 · doc4.xml · nonDerivative · entry 4 Fernandez Henry A · CIK 0001416750 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Daughter Disclosed balance after: 7,900 F2 · shares: Bona fide gift by the Reporting Person to his daughter. Read SEC document |
| December 21, 2021 Filed Feb 9, 2022 16:15 UTC | MSCI Inc. MSCI · Entity 3075 | GiftCommon Stock | 7,170 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-008021 · doc4.xml · nonDerivative · entry 3 Fernandez Henry A · CIK 0001416750 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,676,495 F2 · shares: Bona fide gift by the Reporting Person to his daughter. Read SEC document |
| December 21, 2021 Filed Feb 9, 2022 16:15 UTC | MSCI Inc. MSCI · Entity 3075 | GiftCommon Stock | 4,275 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-008021 · doc4.xml · nonDerivative · entry 2 Fernandez Henry A · CIK 0001416750 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Son Disclosed balance after: 7,900 F1 · shares: Bona fide gift by the Reporting Person to his son. Read SEC document |
| December 21, 2021 Filed Feb 9, 2022 16:15 UTC | MSCI Inc. MSCI · Entity 3075 | GiftCommon Stock | 4,275 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-008021 · doc4.xml · nonDerivative · entry 1 Fernandez Henry A · CIK 0001416750 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,683,665 F1 · shares: Bona fide gift by the Reporting Person to his son. Read SEC document |
| September 30, 2021 Filed Sep 30, 2021 19:17 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 992 | $37.80 | $37,499.19 |
DisclosureSEC source: 0001209191-21-058159 · doc4.xml · nonDerivative · entry 1 Fernandez Henry A · CIK 0001416750 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,978 F1 · price: Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500. Read SEC document |
| June 30, 2021 Filed Jun 30, 2021 21:50 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 871 | $43.04 | $37,489.23 |
DisclosureSEC source: 0000950103-21-009790 · dp153694_4-fernandez.xml · nonDerivative · entry 1 Fernandez Henry A · CIK 0001416750 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,986 F1 · price: Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500. Read SEC document |
| June 25, 2021 Filed Jun 30, 2021 00:28 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 5,726 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-21-009689 · dp153553_4-fernandez.xml · nonDerivative · entry 1 Fernandez Henry A · CIK 0001416750 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,115 F1 · shares: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder. F2 · balance_after: Reflects an adjustment to the number of Class A Ordinary Shares beneficially owned by the reporting person based on the actual number of shares delivered to the reporting person upon the settlement of an award of restricted stock units granted to the reporting person as reported on August 13, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.